1. Home
  2. IRD vs BATL Comparison

IRD vs BATL Comparison

Compare IRD & BATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • BATL
  • Stock Information
  • Founded
  • IRD 2018
  • BATL 1987
  • Country
  • IRD United States
  • BATL United States
  • Employees
  • IRD N/A
  • BATL N/A
  • Industry
  • IRD
  • BATL Oil & Gas Production
  • Sector
  • IRD
  • BATL Energy
  • Exchange
  • IRD NYSE
  • BATL Nasdaq
  • Market Cap
  • IRD 36.0M
  • BATL 29.9M
  • IPO Year
  • IRD N/A
  • BATL N/A
  • Fundamental
  • Price
  • IRD $1.14
  • BATL $1.62
  • Analyst Decision
  • IRD Strong Buy
  • BATL
  • Analyst Count
  • IRD 1
  • BATL 0
  • Target Price
  • IRD $8.00
  • BATL N/A
  • AVG Volume (30 Days)
  • IRD 144.6K
  • BATL 103.2K
  • Earning Date
  • IRD 02-19-2025
  • BATL 03-28-2025
  • Dividend Yield
  • IRD N/A
  • BATL N/A
  • EPS Growth
  • IRD N/A
  • BATL N/A
  • EPS
  • IRD N/A
  • BATL N/A
  • Revenue
  • IRD $8,381,000.00
  • BATL $191,482,000.00
  • Revenue This Year
  • IRD N/A
  • BATL $2.21
  • Revenue Next Year
  • IRD $29.37
  • BATL N/A
  • P/E Ratio
  • IRD N/A
  • BATL N/A
  • Revenue Growth
  • IRD N/A
  • BATL N/A
  • 52 Week Low
  • IRD $0.81
  • BATL $1.31
  • 52 Week High
  • IRD $2.71
  • BATL $7.37
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • BATL 38.47
  • Support Level
  • IRD N/A
  • BATL $1.62
  • Resistance Level
  • IRD N/A
  • BATL $1.97
  • Average True Range (ATR)
  • IRD 0.00
  • BATL 0.16
  • MACD
  • IRD 0.00
  • BATL 0.02
  • Stochastic Oscillator
  • IRD 0.00
  • BATL 1.54

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About BATL Battalion Oil Corporation

Battalion Oil Corp is an independent oil and gas producer operating exclusively in the Delaware Basin. It is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the United States. The company operates in one segment which focuses on oil and natural gas acquisition, production, exploration, and development.

Share on Social Networks: